Table 2 Subgroup analysis of the impact of psoriasis on maternal and neonatal outcome based on odds ratio

LBW¹

1.28(1.18–1.37)

0.0

0.792

0.95(0.83–1.08)

-

-

2.08(0.94–4.59)

-

-

1.19(0.88–1.61)

86.7

0.001

1.26(1.14–1.39)

0.0

0.659

PTB²

1.10(0.99–1.23)

0.0

0.885

1.07 (1.1–1.13)

78.7

0.001

1.33(1.21–1.47)

63.4

0.042

1.12(1.05–1.19)

77.9

0.0001

1.13(1.06–1.19)

804

0.002

CM³

0.87(0.76–1.01)

0.0

0.325

1.01(0.90–1.13)

-

-

1.57(1.08–2.26)

-

-

1.23(0.81–1.85)

74.5

0.020

0.87(0.76–1.01)

-

-

SGA⁴

1.11(1.04–1.18)

0.0

0.778

1.02(0.96–1.09)

0.0

0.647

1.08(0.90–1.29)

85.2

0.001

1.08(1.02–1.15)

58.9

0.023

1.05(0.99–1.13)

33.4

0.212

AS⁵

1.40(1.11–1.77)

0.0

0.690

0.90(0.76–1.07)

-

0.636

-

-

-

1.10(0.75–1.60)

67.6

0.026

1.35(1.01–1.81)

-

-

SB⁶

1.49(1.22–1.84)

0.0

0.924

1.02(0.70–1.50)

42.3

0.177

1.28(0.25–6.50)

-

-

1.12(0.69–1.82)

51.8

0.101

1.33(1.11–1.60)

0.0

0.335

PRE⁷

1.44(1.17–1.78)

51.7

0.126

1.12(1.04–1.21)

0.0

0.637

1.36(1.22–1.52)

0.0

0.565

1.32(1.17–1.50)

45.7

0.117

1.24(1.01–1.53)

79.5

0.002

CD⁸

1.21(0.99–1.47)

80

0.0001

1.36(1.03–1.79)

87.2

0.001

1.25(1.02–1.54)

79.5

0.002

1.19(1.08–1.30)

75.8

000.1

1.42(1.06–1.90)

87.7

0.001

GD⁹

1.22(1–1.49)

55.4

0.134

1.28(1.16–1.41)

0.0

0.727

1.27(1.17–1.38)

0.0

0.797

1.20(1.04–1.39_)

48

0.125

GH¹⁰

1.42(1.12–1.80)

-

-

1.26(1.11–1.42)

25.8

0.260

1.58(1.13–2.21)

-

-

1.25(1.03–1.51)

28.2

0.248

1.38(1.22–1.56)

0.0

0.797